Regeneron Pharmaceuticals stock has delivered a 20.2% return over the past year, and with a high value score plus an undervalued read on market multiples, the current price invites a closer look at whether investors are still paying less than the business might be worth.

• Over the last 12 months, Regeneron Pharmaceuticals shares are up 20.2%, which puts recent gains firmly on the side of existing holders while raising the bar for new buyers.
• Regulatory momentum around cemdisiran for generalized myasthenia gravis and other pipeline partnerships can support expectations for future cash generation, but setbacks in trials or approvals could quickly change how the market prices that potential.
• On Simply Wall St’s broader checks, Regeneron Pharmaceuticals screens as undervalued in 6 of 6 valuation metrics, which points to a stock that still leans cheap across several common yardsticks.

The issue now is whether that combination of past returns and strong valuation checks leaves enough upside to justify buying into Regeneron Pharmaceuticals at current levels.

Is Regeneron Pharmaceuticals a Bargain on Earnings?

The P/E multiple works well for Regeneron Pharmaceuticals because the company is profitable and has an established earnings base. Regeneron trades on a P/E of about 15.0x, below both the biotech industry average of 17.3x and a wider peer group at 37.4x, which puts the stock at a discount on straightforward earnings terms.

A more tailored benchmark that factors in Regeneron Pharmaceuticals' size, sector and risk profile points to a fair P/E of about 24.8x, meaning the current multiple sits well under what that framework would suggest. Despite recent attention around cemdisiran and other partnerships, the market is still valuing each dollar of Regeneron earnings more cautiously than both peers and this fair ratio imply.

On this P/E yardstick, Regeneron Pharmaceuticals stock appears undervalued relative to what its earnings profile would typically command.

The Regeneron Pharmaceuticals Narrative: What Would Justify Today's Price?

For Regeneron Pharmaceuticals, Simply Wall St Narratives sit between the P/E discount described above and the reasons that discount might close or widen. They spell out what would need to happen to the company’s growth, margins and earnings for the stock to be worth materially more or less than today’s price. Each one treats fair value as a thesis about Regeneron Pharmaceuticals' business that can be revisited over time rather than a static number.

Community views on Regeneron Pharmaceuticals sit on a wide spectrum, from underappreciated cash engine to fully priced execution risk.

Bull case: 21% undervalued

"Expansion into high-growth indications such as obesity and cardiometabolic diseases and strategic development for emerging market access create new multi-billion-dollar revenue streams likely underappreciated by the market, supporting higher long-term earnings and revenue diversification..."

Bear case: roughly fairly valued

"Regeneron's heavy reliance on EYLEA and now EYLEA HD for a substantial portion of overall revenues leaves it acutely vulnerable to mounting biosimilar competition and alternative therapies following patent expirations, risking a rapid erosion of top-line growth and earnings stability..."

Do you think there's more to the story for Regeneron Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Regeneron Pharmaceuticals still screens as undervalued on earnings multiples, with the current P/E sitting below both industry and tailored fair-value comparisons. That points to a market that is pricing its cash generation and pipeline with some caution despite solid profitability. For you, the key question is whether concern around concentration in EYLEA and execution on newer indications is justified, or whether the discount reflects an overly conservative view that could close if the pipeline and diversification efforts progress as hoped.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.